Risk factors and outcomes for steroid-refractory immune-related hepatotoxicity in locally advanced and metastatic cancer
Cancer Immunology, Immunotherapy · 2026
DOI: 10.1007/s00262-025-04287-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Songlin Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Medicine, Shandong Second Medical University, Weifang, China. Hauptthemen laut MEDLINE: Chemical and Drug Induced Liver Injury, Immune Checkpoint Inhibitors, Neoplasms, Steroids. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province, Cultivating Fund of The First Affiliated Hospital of Shandong First Medical University.
Abstract (Originalsprache)
Immune-related hepatotoxicity (IRH) is one of the common immune-related adverse events caused by immune checkpoint inhibitors (ICIs). Some patients with steroid-refractory IRH (Ref-IRH) are potentially life-threatening. This study was designed to determine the risk factors and outcomes for Ref-IRH. Locally advanced or metastatic cancer patients who developed steroid-responsive IRH (Res-IRH) or Ref-IRH were identified between December 1, 2019 and September 1, 2024. Patient characteristics, peripheral blood biomarkers, and cytokine levels were collected. In this cohort of 480 patients treated with immune checkpoint inhibitors, 35 patients (7.3%) developed IRH, including 12 with Res-IRH and 13 with Ref-IRH. Patients with Ref-IRH were more likely to be hepatocellular carcinoma (p = 0.035), receive ICIs plus targeted therapy (p = 0.046), and have higher CTCAE grades (p = 0.044) at diagnosis. Patients with Ref-IRH had lower platelet counts (p = 0.006), higher procalcitonin levels (p = 0.012), and higher IL-6 levels (p = 0.038). Univariate logistic regression analysis indicated that higher IL-6 at diagnosis was a potential risk factor for Ref-IRH (p = 0.019). All Ref-IRH patients were treated with immunosuppressive agents. The survival outcomes of Ref-IRH were comparable to those of Res-IRH. Patients with Ref-IRH were unlikely to quickly recover with a longer time from initial diagnosis of IRH to resolution to grade 1 (p = 0.002), from peak ALT (p = 0.007), AST (p = 0.011), and TBIL (p = 0.048) to resolution to grade 1, from initial diagnosis of IRH to use of prednisone ≤ 20 mg/day (p = 0.025), and prolonged hospital length of stay (p = 0.017). In conclusion, high IL-6 at diagnosis is a potential risk factor for the development of Ref-IRH. There was no significant difference in efficacy and survival between patients with Ref-IRH and Res-IRH, but much more time from the initial diagnosis of IRH to resolution to grade 1 and the use of immunosuppressive agents is needed for Ref-IRH patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Clinical Medicine, Shandong Second Medical University, Weifang, China.
- Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, China.
- Shandong Lung Cancer Institute, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, China.
- Lung Cancer Center, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, China.
- Department of Oncology, The 960 Hospital of the People's Liberation Army, Jinan, China.
- Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, China. ggjun2005@126.com.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Cultivating Fund of The First Affiliated Hospital of Shandong First Medical University
- CSCO-MSD Cancer Research Foundation
- CSCO-PILOT Cancer Research Foundation
- Wu Jieping Medical Foundation for Clinical Scientific Research
Zitieren
APA
Liu, S., Zhang, Y., Guan, Y., Xie, H., Dong, Y., Chang, J., Xie, Q., Wang, B., & Wang, J. (2026). Risk factors and outcomes for steroid-refractory immune-related hepatotoxicity in locally advanced and metastatic cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04287-7
Vancouver
Liu S, Zhang Y, Guan Y, Xie H, Dong Y, Chang J, et al. Risk factors and outcomes for steroid-refractory immune-related hepatotoxicity in locally advanced and metastatic cancer. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-025-04287-7
BibTeX
@article{Liu2026,
author = {Liu, Songlin and Zhang, Yuekai and Guan, Yaping and Xie, Hong and Dong, Yue and Chang, Jiang and Xie, Qi and Wang, Baocheng and Wang, Jun},
title = {Risk factors and outcomes for steroid-refractory immune-related hepatotoxicity in locally advanced and metastatic cancer},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
doi = {10.1007/s00262-025-04287-7}
}
EUVIMED